These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 10508721)

  • 1. Mechanism of fluoroquinolone action.
    Drlica K
    Curr Opin Microbiol; 1999 Oct; 2(5):504-8. PubMed ID: 10508721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.
    Tse-Dinh YC
    Infect Disord Drug Targets; 2007 Mar; 7(1):3-9. PubMed ID: 17346206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance.
    Hooper DC
    Clin Infect Dis; 1998 Aug; 27 Suppl 1():S54-63. PubMed ID: 9710672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions between fluoroquinolones, Mg2+, DNA and DNA gyrase, studied by phase partitioning in an aqueous two-phase system and by affinity chromatography.
    Khac SB; Moreau NJ
    J Chromatogr A; 1994 May; 668(1):241-7. PubMed ID: 7516247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of action and resistance of older and newer fluoroquinolones.
    Hooper DC
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S24-8. PubMed ID: 10984324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluoroquinolones: action and resistance.
    Drlica K; Malik M
    Curr Top Med Chem; 2003; 3(3):249-82. PubMed ID: 12570763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.
    Anderson VE; Zaniewski RP; Kaczmarek FS; Gootz TD; Osheroff N
    Biochemistry; 2000 Mar; 39(10):2726-32. PubMed ID: 10704224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA cleavage activities of Staphylococcus aureus gyrase and topoisomerase IV stimulated by quinolones and 2-pyridones.
    Saiki AY; Shen LL; Chen CM; Baranowski J; Lerner CG
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1574-7. PubMed ID: 10390205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries.
    Anderson VE; Zaniewski RP; Kaczmarek FS; Gootz TD; Osheroff N
    J Biol Chem; 1999 Dec; 274(50):35927-32. PubMed ID: 10585479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel combination of mutations in the DNA gyrase and topoisomerase IV genes in laboratory-grown fluoroquinolone-resistant Shigella flexneri mutants.
    Chu YW; Houang ET; Cheng AF
    Antimicrob Agents Chemother; 1998 Nov; 42(11):3051-2. PubMed ID: 9867794
    [No Abstract]   [Full Text] [Related]  

  • 11. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins.
    Fernandez-Moreira E; Balas D; Gonzalez I; de la Campa AG
    Microb Drug Resist; 2000; 6(4):259-67. PubMed ID: 11272253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
    Akasaka T; Tanaka M; Yamaguchi A; Sato K
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2263-8. PubMed ID: 11451683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action.
    Strumberg D; Nitiss JL; Dong J; Walker J; Nicklaus MC; Kohn KW; Heddle JG; Maxwell A; Seeber S; Pommier Y
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2735-46. PubMed ID: 12183223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
    Pan XS; Fisher LM
    J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoroquinolone resistance: mechanisms and epidemiology.
    Tillotson GS; Dorrian I; Blondeau J
    J Med Microbiol; 1997 Jun; 46(6):457-61. PubMed ID: 9379475
    [No Abstract]   [Full Text] [Related]  

  • 16. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
    Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanisms for the development of quinolone resistance].
    Kojima M
    Nihon Rinsho; 1997 May; 55(5):1252-60. PubMed ID: 9155183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity of a new fluoroquinolone, DU-6859a, against quinolone-resistant clinical isolates of Neisseria gonorrhoeae with genetic alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV.
    Deguchi T; Yasuda M; Nakano M; Kanematsu E; Ozeki S; Ishihara S; Saito I; Kawada Y
    J Antimicrob Chemother; 1997 Feb; 39(2):247-9. PubMed ID: 9069547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro antimicrobial activity of HSR-903, a new fluoroquinolone, against clinical isolates of Klebsiella pneumoniae and Enterobacter cloacae with fluoroquinolone resistance-associated amino acid alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Kawamura T; Takahashi Y; Okezaki E; Nagata O; Kato H; Kawada Y
    J Antimicrob Chemother; 1997 Dec; 40(6):907-9. PubMed ID: 9462448
    [No Abstract]   [Full Text] [Related]  

  • 20. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage.
    Chen CR; Malik M; Snyder M; Drlica K
    J Mol Biol; 1996 May; 258(4):627-37. PubMed ID: 8636997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.